

# Jessica M. Andrade

GOVERNMENT INVESTIGATIONS VICE CHAIR

she / her / hers

Seattle, WA | 206.393.5422

[jessica.andrade@polsinelli.com](mailto:jessica.andrade@polsinelli.com)



Jessica's practice focuses on defending clients facing government investigations and enforcement proceedings, as well as False Claims Act, Anti-Kickback and Stark litigation. This includes working with clients in both the healthcare and government contracting industries.

Jessica also has significant complex commercial litigation experience representing corporations, officers and directors in class actions, securities litigation and contract disputes and conducting internal investigations on behalf of corporations. She has represented government contractors in disputes with federal and state government, and advised government contracting clients on compliance concerns.

Previously, Jessica served as an Assistant U.S. Attorney in the Affirmative Civil Enforcement Unit of the Civil Division of the U.S. Attorney's Office for the Western District of Washington. While at the U.S. Attorney's Office, Jessica led investigations of financial fraud against the federal government in the context of federal healthcare, defense and other programs. Jessica also defended the United States against civil claims in multiple contexts.

## Education

- University of Michigan Law School (J.D., *cum laude*, 2007)
  - Executive Editor, Michigan Journal of Law Reform
- University of Washington (B.A., *cum laude*, 2003)

## Bar Admissions

- Washington
- Alaska
- Oregon

## Court Admissions

- U.S. District Court, Western District of Washington
- U.S. District Court, Eastern District of Washington

## Capabilities

- Government Investigations
- Health Care Litigation
- False Claims Act Defense
- Internal Investigations
- Commercial Litigation
- Antitrust - Health Care
- Medical Staff Governance, Operations & Disputes
- Litigation
- Post Chevron Educational Resources & Updates

- U.S. District Court, District of Alaska
- U.S. Court of Appeals, Ninth Circuit
- U.S. District Court, District of Oregon
- U.S. Court of Appeals, Eighth Circuit

## Memberships

- Institute for a Democratic Future, Board of Directors, 2016-Present, Fellow, 2013
- Legal Voice, Board of Directors, 2015-2020
- New Beginnings, Board of Directors, 2013-2019
- Leadership Tomorrow, Fellow, 2013-2014
- Seattle Human Rights Commission, Commissioner, Appeals Panel Chair, 2009-2013

## Recognition

- Named “Litigation Star” by *Benchmark Litigation*, 2023-2026
- Selected for inclusion in *Best Lawyers in America*® for:
  - Criminal Defense: White-Collar, 2024-2026
  - Litigation - Health Care, 2023-2026
  - Corporate Compliance Law, 2023-2025
  - Commercial Litigation, 2021-2026
- Selected for *Best Lawyers*® “Lawyer of the Year” in Seattle, Washington, for Litigation – Health Care, 2026
- Ranked in *Chambers USA: America’s Leading Lawyers for Business*, Washington:
  - Litigation: White-Collar Crime & Government, 2021-2025
  - Healthcare, 2023-2025
- Selected for inclusion in *Washington Super Lawyers*, 2022
- Selected for inclusion in *Washington Super Lawyers, Rising Star*, 2013-2014

## Matters

---

- Led internal investigation concerning alleged fraud and conflicts of interest for multimillion-dollar federal healthcare contractor; led self-disclosure and negotiated favorable settlement with federal authorities.
- Obtained dismissal of federal *qui tam* False Claims Act lawsuit alleging false claims related to anesthesiology services.
- Secured declination of federal *qui tam* False Claims Act lawsuit alleging medically unnecessary surgical procedures, valued in the tens of millions of dollars.
- Secured declination of federal *qui tam* False Claims Act lawsuit alleging violation of Medicare Advantage regulations, valued in the tens of millions of dollars.
- Secured closing of nationally prosecuted DOJ case relating to allegations of violations of the Controlled Substances Act requirements for reporting of theft and loss of controlled substances.
- Negotiated favorable settlement after succeeding in dispositive motion hearing on behalf of former CEO in shareholder dispute arbitration.
- Obtained writ of attachment against pharmaceutical company via arbitration for payment due to a clinical trial research administration firm.\*
- Representing major hospital system against federal government investigation of False Claims Act allegations.
- Defending Fortune 500 pharmacy in DOJ investigations concerning opioid prescribing

practices.

- Defending individual against research misconduct allegations relating to pharmaceutical research.

\*Denotes work at prior firm.

## Publications

---

April 13, 2026

**2026 340B Program Update – 340B Rebate Model RFI Comments Due and Manufacturers Continue Restricting 340B Pricing**

August 7, 2025

**The 340B Rebate Pilot: Voluntary for Manufacturers, Costly for 340B Covered Entities**

July 3, 2025

**Supreme Court Halts Nationwide Injunctions with Major Implications for Ongoing Litigation**

June 25, 2025

**DOJ Civil Division Refocuses Affirmative Enforcement Priorities**

May 27, 2025

**DOJ Announces Intent to Use False Claims Act To Target Diversity and DEI Initiatives**

**SCOTUS Rejects Defense-Friendly Scierter Standard In Schutte Opinion**

April 13, 2023

**DOJ Continues to Target Lab Sales Arrangements and Ordering Practices**

April 5, 2023

**False Claims Act: Appellate Court Deepens Circuit Split in Favor of Healthcare Defendants**

February 21, 2023

**False Claims Act Recoveries 2022**

September 22, 2022

**DOJ Strengthens Efforts to Combat Corporate Crime with Increased Focus on Individual Culpability and Self-Disclosure**

September 15, 2022

**Health Care Reimbursement and Payor Dispute Update**

June 16, 2022

**SCOTUS Sides with 340B Hospitals and Denies CMS's Attempt to Cut Reimbursement for 340B Drugs**